Table 2.
Clinical information from the eligible trials in the meta-analysis
| Included studies | Nation | D-S stage | Patients, Con/Exp | Age (years)
|
Parameter types | |
|---|---|---|---|---|---|---|
| Con | Exp | |||||
| Ding (2013)14 | China | II–III | 16/14 | 71.3±4.0 (mean) | 70.5±3.4 (mean) | ORR |
| Gao (2015)15 | China | III | 60/60 | 48.2±3.4 (mean) | 47.8±3.6 (mean) | ORR, DCR, cytokines, Kps |
| Lu (2015)16 | China | I–III (ISS) | 12/10 | 60 (median) | 61 (median) | Treg, ORR, DCR |
| Sun (2012)17 | China | II–III | 24/24 | 58.2±15.4 (mean) | 59.8±17.8 (mean) | ORR, DCR, TC, β2-M, M, ULC, Scr, AgNOR, cytokines |
| Tan (2016)18 | China | ND | 30/30 | 58.6±8.8 (mean) | 59.6±9.2 (mean) | LYM subsets, ORR, cytokines, ADE |
| Wang (2015)19 | China | II–III | 14/15 | 61.4±3.5 (mean) | 60.7±4.0 (mean) | ORR, DCR |
| Yan (2014)20 | China | ND | 18/22 | ND | ND | ORR, DCR, TC, β2-M, Scr |
| Ye (2016)21 | China | ND | 16/17 | ND | ND | ORR |
| Yu (2016)22 | China | I–III | 30/30 | 57.6±5.3 (mean) | 59.3±4.3 (mean) | LYM subsets, ORR, DCR |
| Zhao (2015)23 | China | I–III (ISS) | 24/26 | 56.3±10.6 (mean) | 57.1±11.8 (mean) | LYM subsets, cytokines, TC, β2-M, M, ULC, Scr, Ps |
| Zhao (2016)24 | China | I–III (ISS) | 20/22 | 56.5±12.7 (mean) | 57.6±13.5 (mean) | Treg, TC, β2-M, M, ULC, Scr, Ps |
| Zhong (2012)25 | China | I–III (ISS) | 30/30 | 58.2±15.4 (mean) | 61.8±17.8 (mean) | ORR, DCR, TC, β2-M, ULC, Scr, Ps |
Notes: Con, control group (chemotherapy alone group); Exp, experimental group (chemotherapy plus DC–CIK immunotherapy); M, serum level of M protein; β2-M, serum level of β2-microglobin; ULC, 24 h urine light chain content.
Abbreviations: ADE, adverse events; AgNOR, silver-staining nucleolar organizer region; DC–CIK, dendritic cells and cytokine-induced killer cells; DCR, disease control rate; D–S, Durie–Salmon; ISS, International Staging System; Kps, Karnofsky performance score; LYM, lymphocyte; ND, nondetermined; ORR, overall response rate; Ps, performance status; Scr, serum creatinine; TC, tumor cell.